NASDAQ: RPRX
Royalty Pharma PLC Earnings Dates, Reports, Calls

Royalty Pharma earnings were $1.0B for the trailing 12 months ending Jun 30, 2025, with 53% growth year over year. The latest RPRX earnings report on Jun 30, 2025 announced Q2 2025 earnings of $30.2M, down 87.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RPRX reported annual earnings of $859.0M, with -24.3% growth.

RPRX past earnings growth

How has RPRX's earnings growth performed historically?

Company
52.98%
Industry
31.33%
Market
29.72%
RPRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RPRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
RPRX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

RPRX earnings history

Current Revenue
$2.3B
Current Earnings
$1.0B
Current Profit Margin
44.3%

RPRX Return on Equity

Current Company
10.2%
Current Industry
-9.6%
Current Market
31.7%
RPRX's Return on Equity (10.2%)... subscribe to Premium to read more.
High Return on Equity Performance

RPRX undefined

Current Company
5.7%
Current Industry
0%
RPRX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RPRX announces earnings.

RPRX undefined

Current Company
7.52%
Current Industry
7.7%
RPRX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RPRX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RPRX$1.29B$1.02B-1.86%$2.31
BNTX-$27.18M-$405.65MN/A-$1.68
SMMT-$737.29M-$746.08MN/A-$0.01
INSM-$914.73M-$1.01BN/A-$5.93
INCY$1.36B$870.87M+30.16%$4.42

Royalty Pharma Earnings Reports & History FAQ

What were Royalty Pharma's earnings last quarter?

On RPRX's earnings call on Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q2 2025 earnings per share (EPS) of $0.07, up 69.57% year over year. Total RPRX earnings for the quarter were $30.18 million. In the same quarter last year, Royalty Pharma's earnings per share (EPS) was $0.23.

If you're new to stock investing, here's how to buy Royalty Pharma stock.

Is Royalty Pharma profitable or losing money?

As of the last Royalty Pharma earnings report, Royalty Pharma is currently profitable. Royalty Pharma's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $1.02 billion, a 51.61% increase year over year.

What was RPRX's earnings growth in the past year?

As of Royalty Pharma's earnings date in Invalid Date, Royalty Pharma's earnings has grown 52.98% year over year. This is 21.65 percentage points higher than the US Biotechnology industry earnings growth rate of 31.33%. RPRX earnings in the past year totalled $1.02 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.